First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - August (BATS: AUGM)

Latest news for First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - August (BATS:AUGM)

FT Vest US Equity Max Buffer ETF - August

First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - August

AUGUSTUS MINERALS LTD by AUGUSTUS MINERALS LTD

AUGMEDIX INC COM

News

FTII

FutureTech II Finds Accounting Errors Affecting 2023 Financials; Restatement In Progress For Q3 2023, Q1 & Q2 2024; Overpayment To Shareholders And Extension Loans Issues; Material Weakness In Controls Admitted; Filing Of Amended Reports With SEC Pending

WIIM

UPST

Upstart Holdings shares are trading higher after Needham upgraded the stock from Hold to Buy and announced a $100 price target.

NVCR

NovoCure shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $28 to $42.

Shares of SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) are trading higher Friday following a series of favorable announcements highlighting the company's advancements in conversational AI technology. Here&#8217;s <a href="https://www.benzinga.com/quote/SOUN/news">what you need to know.</a>
What To Know: On Thursday, the company's Amelia Conversational AI Platform was recognized as a leader in Frost &amp; Sullivan's 2024 Frost Radar: Enterprise Conversational AI in Healthcare. The report identified SoundHound AI among 14 market leaders out of more than 100 vendors analyzed, citing its innovation and growth in transforming healthcare operations. The platform leverages advanced natural language processing and large language models to improve patient engagement and streamline administrative workflows, including appointment scheduling and IT support.
&#8220;SoundHound&#8217;s Conversational AI Platform stands out for its exceptional performance on both innovation and growth indices is driven by its strong innovation pipeline and an intelligent focus on administrative and operational processes for healthcare organizations,&#8220;said&nbsp;Nitin Manocha, Senior Industry Analyst at Frost &amp; Sullivan.&nbsp;
The Frost &amp; Sullivan report also projected that the enterprise conversational AI market in healthcare would reach $2.34 billion by 2027, growing at a compound annual rate of 17.2%. Analysts noted that SoundHound's acquisition of Amelia positions the company among the largest publicly traded conversational AI firms, with opportunities to expand use cases and deliver value in healthcare.
&#8220;With SoundHound&#8217;s recent acquisition of Amelia, the company now ranks among the largest publicly traded conversational AI companies. By integrating SoundHound&#8217;s advanced voice AI capabilities with Amelia&#8217;s enterprise platform, the company has a tremendous opportunity to unlock more complex use cases and drive real value in the healthcare sector,&#8221; added Manocha.
Additionally, SoundHound announced a partnership with Church's Texas Chicken to implement a voice AI-powered drive-thru ordering solution. The initiative aims to streamline operations, reduce wait times, and enhance staff efficiency.
&#8220;Integrating our technology into Church&#8217;s Texas Chicken restaurants marks a significant milestone in drive-thru innovation,&#8221;&nbsp;said&nbsp;James Hom, Chief Product Officer at SoundHound AI.&nbsp;
SOUN Price Action: SoundHound shares were up 24.8% at $17.05 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-1024x542.png" alt="" class="wp-image-692135" style="width:470px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42490912/teamsters-authorize-strike-at-amazons-new-york-warehouses-get-ready-for-a-fight">Teamsters Authorize Strike At Amazon&#8217;s New York Warehouses: &#8216;Get Ready For A Fight&#8217;</a></li>
</ul>
Image Via Shutterstock.

Movers

SOUN

SoundHound AI Shares Are Surging Friday: What You Need To Know

Invitation Homes's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) short percent of float has fallen 10.47% since its last report. The company recently reported that it has 10.74 million shares sold short, which is 2.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Invitation Homes Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Invitation Homes has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Invitation Homes's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Invitation Homes's peer group average for short interest as a percentage of float is 2.36%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

INVH

Looking Into Invitation Homes's Recent Short Interest

Gartner's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) short percent of float has risen 5.65% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gartner Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gartner has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gartner's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gartner's peer group average for short interest as a percentage of float is 3.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Gartner's Recent Short Interest

Summit Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NYSE">SMMT</a>) short percent of float has risen 5.27% since its last report. The company recently reported that it has 16.84 million shares sold short, which is 14.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Summit Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Summit Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Summit Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Summit Therapeutics's peer group average for short interest as a percentage of float is 4.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SMMT

How Is The Market Feeling About Summit Therapeutics?

Value Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALU#NASDAQ">VALU</a>) reported quarterly earnings of $0.60 per share. This is a 62.16 percent increase over earnings of $0.37 per share from the same period last year. The company reported $8.84 million in sales this quarter. This is a 8.00 percent decrease over sales of $9.61 million the same period last year.

Earnings

VALU

Value Line Q2 EPS $0.60 Up From $0.37 YoY, Sales $8.84M Down From $9.61M YoY

AUMN

Golden Minerals Shares Halted, News Pending

Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares are trading lower Friday. The company reported its fourth-quarter results on Wednesday. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/12/42449013/adobe-q4-earnings-revenue-eps-beat-on-strong-demand-related-to-ai-shares-slide-following-soft-guidance">what you need to know.</a>
What To Know: On Wednesday, Adobe reported fourth-quarter revenue of $5.61 billion, beating the $5.54 billion consensus. Adjusted earnings were $4.81 per share, above the $4.66 estimate. This marks Adobe&#8217;s eighth consecutive quarter of beating expectations. Total revenue grew 11% year-over-year, with Digital Media and Digital Experience revenues up 12% and 10%, respectively. Remaining performance obligations (RPO) rose 16% to $19.96 billion. Operating cash flow was $2.92 billion and 4.6 million shares were repurchased during the quarter according to Benzinga Pro.
CEO Shantanu Narayen highlighted record fiscal 2024 revenue and the importance of Adobe&#8217;s cloud platforms in the AI economy.
Guidance: Revenue is projected between $23.3 billion and $23.55 billion, below the $23.79 billion consensus. Adjusted earnings per share are expected to range from $20.20 to $20.50, slightly below the $20.55 estimate. First-quarter revenue guidance of $5.63 billion to $5.68 billion also missed the $5.73 billion consensus. Management pointed to lower pricing benefits, delayed monetization of generative AI solutions and foreign exchange headwinds as factors weighing on growth.
Analysts Ratings: 
<ul>
<li>Piper Sandler: Brent Bracelin maintained an Overweight rating but lowered the price target from $635 to $600.</li>
<li>Oppenheimer: Brian Schwartz reiterated an Outperform rating with a reduced price target of $600.</li>
<li>Goldman Sachs: Kash Rangan reaffirmed a Buy rating and $640 price target.</li>
<li>KeyBanc Capital Markets: Jackson Ader maintained an Underweight rating and $450 price target.</li>
<li>RBC Capital Markets: Matthew Swanson lowered the price target from $610 to $590 while maintaining an Outperform rating.</li>
<li>UBS: Reduced its price target to $525 with a Neutral rating.</li>
<li>Barclays: Adjusted its price target to $645, maintaining an Overweight rating.</li>
<li>Bernstein: Cut its price target to $587, reiterating an Outperform rating.</li>
<li>DA Davidson: Revised its target to $625 while retaining a Buy rating.</li>
<li></li>
</ul>
ADBE Price Action: Adobe shares were down 3.47% at $458.18 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="555" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13143850/yfj-1024x555.png" alt="" class="wp-image-692116" style="width:446px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13143850/yfj-1024x555.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13143850/yfj-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13143850/yfj-768x416.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13143850/yfj.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li></li>
</ul>
Image via Shutterstock.

ADBE

Adobe Shares Are Falling Today: What's Going On?

<a href="https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines">https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines</a>
&nbsp;
<a href="https://www.wsj.com/market-data/quotes/JNJ">Johnson &amp; Johnson</a> has sued divisions of health insurer <a href="https://www.wsj.com/market-data/quotes/CI">Cigna</a>, accusing them of working with a drug-benefit middleman to drain J&amp;J <a href="https://www.wsj.com/articles/patients-lose-access-to-free-medicines-amid-spat-between-drugmakers-health-plans-cca15b58?mod=article_inline">financial-assistance funds earmarked for patients</a> taking some of its pricier drugs.
The move by J&amp;J widens litigation the healthcare giant <a href="https://www.wsj.com/articles/j-j-sues-drug-benefit-middleman-over-use-of-drug-cost-assistance-program-11651698029?mod=article_inline">initiated in 2022</a> against a middleman, SaveOnSP LLC, and is a new flare-up of long-running tension over drug prices among manufacturers, insurers, pharmacy-benefit managers and other middlemen in recent years.

Legal

"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical company claims Cigna units worked with SaveOn and caused it to pay more than $100 million in copay assistance than it would have otherwise" - WSJ

Issues surrounding health care and health insurance coverage are not new for Americans. However, a new study from the Commonwealth Fund shows that gaps in coverage are growing and those who suffer the most are low-income families and people with chronic illnesses.&nbsp;
The study reveals that in 2023, 49 million Americans – 16% of the population – were underinsured, meaning while they had health insurance, their coverage had gaps that left them without the care they needed. This number doesn't include the 26 million Americans (8% of the population) without health insurance coverage.&nbsp;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
In 2024, those numbers have grown, with 35% of Americans being underinsured or facing a coverage gap and 9% not being insured at all. Of the underinsured adults, two-thirds are covered through an <a href="https://www.benzinga.com/personal-finance/24/08/40624190/aon-predicts-9-increase-in-employer-health-care-costs-for-2025-heres-whats-fueling-the-spike">employer plan</a>, while others have Medicare, Medicaid or individual and marketplace plans.&nbsp;
The study also indicated that health care costs prevent many Americans from seeking the care they need in a timely manner. Among the underinsured, 57% reported that they avoided necessary health care due to the costs and 41% said their health worsened.&nbsp;
the Commonwealth Fund is not the only organization that has revealed concerns about health insurance. KFF also shared a report earlier this year in which they polled Americans and found that the high cost of health care plays a major role in health-related decisions, like whether or not to have health insurance and when to get care.&nbsp;
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
According to KFF, about half U.S. adults say it is difficult to afford health care costs and 61% of uninsured adults said they went without care altogether because of the cost. The <a href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs">cost of prescription drugs</a> also prevents people from taking the medications they need – about 21% of adults didn't fill prescriptions due to the cost.&nbsp;
These systemic challenges are not just numbers on a report – they have profound human impacts, often with devastating consequences. A recent high-profile tragedy has brought renewed attention to the personal toll of denied insurance claims and the emotional strain experienced by individuals navigating the <a href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare">U.S. health care system</a>.
Trending: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
Following the murder of United Healthcare CEO Brian Thompson on Dec. 4, Americans stormed social media with their stories of frustration with United Healthcare and other insurance companies.&nbsp;
One user on X, @ProfYolonda, stated that United Healthcare "denied my surgery two days before it was scheduled. I was in the hospital finance office in tears (when I was supposed to be at the hospital doing pre-op stuff). My mother was flying out to see me. My surgeon spent a day and a half pleading my case to United when she probably should have been taking care of her other patients." The post has over 86,000 likes and almost seven million views.&nbsp;
Another X user, @Belinda_McBride, shared that her insurance "slow-walked" her treatment for over 11 years, prolonging her chronic pain until she was eventually able to get the life-changing surgery she needed. "Chronic pain will drive you nuts," she wrote. "It&#8217;s the worst, most dark place you can descend into. I&#8217;m now picking up the pieces of my years in hell."
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Many Americans must jump through multiple hoops before getting the treatment they need. Sara Collins, senior scholar at the Commonwealth Fund, told CNN that getting any kind of denial or delay of care – that a doctor recommended – is scary. "To have a decision all of a sudden be being made on the basis of financing is terribly upsetting for families."
the Commonwealth Fund's findings, paired with personal accounts of denied care, highlight a critical issue in the U.S. As the country grapples with rising health care costs and growing inequities in care, the Commonwealth Fund says that more work is needed to cover these gaps and ensure that health insurance does what it is supposed to do: get people the care they need without <a href="https://www.benzinga.com/personal-finance/24/09/40797492/grant-cardone-slams-dave-ramseys-anti-debt-approach-as-middle-class-thinking-reveals-elon-musks-">fear of going into debt</a>.&nbsp;
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Is U.S. Health Insurance Failing The Sickest And Poorest? New Study Reveals 49 Million Americans Lack Proper Health Coverage

In the current session, Vale Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) is trading at $9.24, after a 2.38% decrease. Over the past month, the stock decreased by 5.76%, and in the past year, by 39.18%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1734121813_0.png" alt="Past Year Chart" />

<h3>A Look at Vale P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Vale has a lower P/E than the aggregate P/E of 20.63 of the Metals &amp; Mining industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734121813_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

VALE

Price Over Earnings Overview: Vale

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) surged 11.3% to $121.33 on Friday, buoyed by Broadcom&#8217;s robust earnings and optimistic AI growth projections, which highlighted the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant">vast opportunities</a> in the custom chip (ASIC) market.
Both companies are major players in developing ASICs tailored for hyperscale AI infrastructure, essential for data centers supporting advanced AI workloads.
What Happened: Broadcom revealed its AI-related revenue is set to grow from $15-$20 billion in 2024 to $60-$90 billion by 2027, driven by surging demand from hyperscalers like Google.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant">Broadcom Hits $1 Trillion Milestone: The Next Magnificent Tech Giant?</a>
While Broadcom leads in deploying 3nm ASICs, Marvell is well-positioned to benefit from this trend, serving overlapping customers with a complementary portfolio of custom chips and networking solutions critical for AI cluster performance.
The AI market's rapid expansion, with Broadcom projecting a 40%-50% annual growth rate in AI revenues, validates strong demand for ASIC technology. Marvell's expertise in high-speed data transport and networking, which connects compute nodes in AI systems, aligns it with this momentum.
Investors might see Marvell as a natural beneficiary of the growing AI serviceable available market (SAM), as it strengthens partnerships with hyperscalers and accelerates its own next-gen ASIC roadmap.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a>
<h2 class="wp-block-heading">Is MRVL A Good Stock To Buy?</h2>
Wall Street analysts view Marvell Technology on the whole as a Outperform, given the history of coverage over the past three months. Christian Schwab from Craig-Hallum in Marvell Tech is the most optimistic, expecting a 50.0% rise in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Marvell Tech rose 61.12%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 6.84% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $121.86 and a 52-week low of $53.19.

MRVL

Why Marvell Technology (MRVL) Stock Is Skyrocketing

In the current session, the stock is trading at $176.02, after a 0.54% increase. Over the past month, Masimo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) stock increased by 9.28%, and in the past year, by 52.77%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734120953_0.png" alt="Past Year Chart" />

<h3>Masimo P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Masimo has a better P/E ratio of 120.74 than the aggregate P/E ratio of 65.12 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that Masimo Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734120953_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

MASI

A Look Into Masimo Inc's Price Over Earnings

QBTS

D-Wave Quantum shares are trading higher. The stock may be moving in sympathy with Google which recently released its Willow Quantum Computing chip.

SkyBridge Capital founder Anthony Scaramucci voiced optimism about the <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42461870/michael-saylor-lauds-bitcoins-100000-milestone-it-will-be-embraced-by-the-worlds-wealthy-and-powerful">state of the crypto market,</a> sharing a personal anecdote to back up his assessment.
What Happened: In an <a href="https://www.dlnews.com/articles/people-culture/anthony-scaramucci-orders-new-lambo-predicts-bipartisan-legislation/?utm_source=twitter&amp;utm_medium=organic_social&amp;utm_campaign=">interview</a> with DL News on Dec. 13, Scaramucci revealed that he's upgrading his 2022 Lamborghini to a 2026 model, reflecting his confidence in the ongoing bull market.
In a light-hearted moment, Scaramucci, who described himself as a "nouveau riche Italian from Long Island," joked, "My life's dream is to have a Lamborghini." 
When asked if he sold any of his Bitcoin to finance the new purchase, he firmly responded, "Why would I f&#8212;ing sell my Bitcoin?"
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42490266/bitcoin-to-180000-ethereum-over-6000-solana-to-500-vanecks-2025-crypto-predictions">Bitcoin To $180,000, Ethereum Over $6,000, Solana To $500: VanEck's 2025 Crypto Predictions</a>
Why It Matters: His confidence is backed by a rising cryptocurrency market capitalization, which has surged 20% in the past 30 days to $3.6 trillion, driven by Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rise to $100,000, with altcoins and meme coins also seeing growth.
Scaramucci also stressed the growing bipartisan support for <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42480856/donald-trump-pledges-to-do-something-great-with-crypto-heres-what-hes-done-so-far">crypto legislation</a>, noting that the 2024 election cycle has increased awareness among lawmakers, especially with the financial contributions the crypto industry has made.
In another interview, Scaramucci shared his belief that Bitcoin is primed for <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378636/scaramucci-bitcoin-is-a-volatile-asset-but-ready-for-prime-time-institutional-investing">mainstream institutional investment</a>. He also noted that more people in the U.S. now own crypto than own dogs, a sign of the growing acceptance of digital assets.
Scaramucci, a veteran in the industry, pointed out a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue">three-year delay in the crypto rally</a> due to the Democrats&#8217; anti-crypto stance, but he believes the incoming administration under Trump will play a key role in shaping future crypto policy.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42482174/bitcoins-tug-of-war-around-100000-where-does-the-btc-price-go-from-here">Bitcoin's Tug-of-War Around $100,000: Where Does The BTC Price Go From Here?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci Upgrades His Lamborghini—But Not At The Cost Of Selling Bitcoin: 'Why Would I Sell?'

Barrington Research analyst Gary Prestopino maintains Liquidity Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) with a Outperform and raises the price target from $35 to $40.

Price Target

Analyst Ratings

LQDT

Barrington Research Maintains Outperform on Liquidity Services, Raises Price Target to $40

SEALSQ's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NYSE">LAES</a>) short percent of float has fallen 9.05% since its last report. The company recently reported that it has 2.37 million shares sold short, which is 8.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SEALSQ Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734120031_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SEALSQ has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SEALSQ's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SEALSQ's peer group average for short interest as a percentage of float is 2.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LAES

Peering Into SEALSQ's Recent Short Interest

Wells Fargo analyst Michael Blum maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $385 to $411.

Wells Fargo Maintains Overweight on GE Vernova, Raises Price Target to $411

FT Vest U.S. Equity Max Buffer ETF - August

Comments

First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - August

News

Latest news for First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - August (BATS:AUGM)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga